This slide show features pathology slides and PET/CT scans of prostate cancer, as well as various images of bone lesions from metastatic disease.
Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC
Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC
Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.
Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas
Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.
Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC
Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.
Time to Progression in mHSPC Cohort Prolonged With Darolutamide
The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.